Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Arius Research begins preparations for phase I clinical trials of cancer-killing antibodies

July 20, 2001

Mechanism of action of Mylotarg in AML elucidated

July 20, 2001

Licensing opportunity from NIH: beta2-microglobulin fusion proteins

July 17, 2001

Positive long-term survival and safety data reported for OvaRex

July 16, 2001

MabCampath approved in Europe for B-CLL

July 13, 2001

TheraCIM h-R3 enters phase I/II for additional indication

July 12, 2001

Pharmexa begins phase I/II trial of therapeutic vaccine for breast cancer in Denmark

July 11, 2001

Ivax boosts immunotoxin program with new agreement

July 11, 2001

PSK evaluated in clinical trials as adjuvant immunochemotherapy in colorectal cancer

July 5, 2001

Combination therapies for certain malignancies discussed by Idec

June 29, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...